Please ensure Javascript is enabled for purposes of website accessibility

Cel-Sci announces reverse stock split

Cel-Sci announces reverse stock split

Listen to this article

Cel-Sci Corp., of Vienna, Va., and Elkridge, a biotechnology company that is developing new immune system-based treatments for cancer and infectious diseases, announced Friday it is implementing a 1-for-10 reverse stock split, effective on Wednesday.

The move is an effort by the company to maintain its New York Stock Exchange listing by raising its stock price. Cel-Sci was warned by the NYSE in July that its stock was in danger of being delisted due to noncompliance with the exchange’s financial condition listing requirement. Cel-Sci’s stock price has recently fluctuated between 16 cents and 19 cents per share. The stock split will reduce the number of shares outstanding from around 310 million to 31 million.

Networking Calendar

Submit an entry for the business calendar